Rheumatoid Arthritis | Disease Landscape & Forecast | G7 | 2024
Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug market boasts a variety of targeted agents from many drug classes, all competing largely for a share of the TNF-refractory population. The continued launch of biosimilars in the major pharmaceutical markets will only add to the competition. Increasing safety concerns surrounding the JAK inhibitor class have pushed back the use of these agents after anti-TNF drugs in the United States, impacting their overall uptake. Although the late-phase pipeline for RA is sparse, the sheer number of biologics and targeted oral therapies available to treat the disease ensures that marketers will face fierce competition and increasing challenges to gain and maintain market share.
Questions answered
- What are physicians’ preferred TNF-alpha inhibitors for RA, and what factors drive this perception? Given the increasingly fragmented market, how likely are physicians to cycle through anti-TNF agents before progressing to a novel mechanism of action?
- How has / will the entry and continued uptake of biosimilars affect sales and patient shares of currently marketed RA agents and emerging therapies?
- What are physicians’ perceptions of currently marketed non-TNF biologics and oral JAK inhibitors for RA? Where are these agents positioned in the treatment algorithm, and which agents have been most successful in targeting the TNF-refractory population?
Content highlights
Markets covered: United States, EU5, Japan
Primary research: Approximately 20 country-specific interviews with thought-leading rheumatologists
Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of RA by country; number of diagnosed prevalent cases of RA by severity
Drug treatments: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations
